CorMedix (CRMD) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Product overview and market positioning

• DefenCath, an antimicrobial catheter lock solution, was approved in November and launched in inpatient settings in April and outpatient in July.

• DefenCath is the first FDA-approved product for reducing catheter-related bloodstream infections in hemodialysis patients.

• Competes mainly with heparin or saline locks; compounded antibiotics are used but have resistance concerns.

• DefenCath combines taurolidine and heparin, offering broad-spectrum activity without observed resistance.

Commercialization progress and agreements

• Outpatient market is highly concentrated, with three of the top five operators under contract.

• Initial rollout with a major outpatient customer targets 4,000 high-risk patients, with shipments expected to begin in Q4.

• Outpatient market represents about 90% of the total addressable market, with inpatient at 10%.

• Inpatient commercialization is a longer process, with a 9–12 month sales cycle.

Launch strategy and operational focus

• Success depends on rapid operationalization of agreements and customer support, especially around reimbursement.

• Customer education is tailored by setting and role, with a call center established for facility reimbursement questions.

• Clinical data shows a 71% reduction in infection rates, aiding communication with stakeholders.